Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho Low-Dose OC, EVRA Patch Will Counter Generics Of Tri-Cyclen In 2003

Executive Summary

Ortho-McNeil's pending contraceptive line extensions will help the company expand the market for hormonal contraceptives, Johnson & Johnson Company Group Chairman Christine Poon said during a May 30 R&D meeting in La Jolla, Calif.

You may also be interested in...



Tri-Cyclen Lo Clears FDA; Ortho-McNeil Patches Up Contraceptive Line

Ortho-McNeil is ready to launch the second pillar in its contraceptive product line defense following the approval of Tri-Cyclen Lo (norgestimate/ethinyl estradiol) Aug. 22

Tri-Cyclen Lo Clears FDA; Ortho-McNeil Patches Up Contraceptive Line

Ortho-McNeil is ready to launch the second pillar in its contraceptive product line defense following the approval of Tri-Cyclen Lo (norgestimate/ethinyl estradiol) Aug. 22

Barr Proprietary R&D Unit May Be Incorporated As Separate Business

Barr is seeking legal advice on whether its proprietary product development unit should remain a division of the company or be incorporated as a separate business.

Related Content

UsernamePublicRestriction

Register

PS037966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel